And MTHFD2 was highly expressed (++ to +++) in 8/10 (80%) cases of metastasis and in 26/62 (41.94%) cases of ovarian serous carcinoma (Fig. 1D). Here, MTHFD2 is linked to ovarian serous carcinoma.